Retrograde popliteal access to treat femoropopliteal artery occlusive disease

Autor: Jeffrey A. Kalish, Denis Rybin, Sevan Komshian, Alik Farber, Jeffrey J. Siracuse, Thomas W. Cheng, Marc L. Schermerhorn, Douglas W. Jones
Rok vydání: 2018
Předmět:
Male
Time Factors
Databases
Factual

medicine.medical_treatment
Kaplan-Meier Estimate
Femoral artery
030204 cardiovascular system & hematology
030230 surgery
0302 clinical medicine
Risk Factors
Popliteal Artery
Aged
80 and over

Endovascular Procedures
Middle Aged
Limb Salvage
Femoral Artery
Treatment Outcome
medicine.anatomical_structure
Female
medicine.symptom
Cardiology and Cardiovascular Medicine
Artery
medicine.medical_specialty
Punctures
complex mixtures
Amputation
Surgical

Disease-Free Survival
Peripheral Arterial Disease
03 medical and health sciences
Hematoma
medicine.artery
Catheterization
Peripheral

medicine
Humans
Vascular Patency
Propensity Score
Aged
Proportional Hazards Models
Retrospective Studies
Chi-Square Distribution
business.industry
Perioperative
medicine.disease
United States
Popliteal artery
Surgery
Amputation
Multivariate Analysis
business
Claudication
Zdroj: Journal of Vascular Surgery. 68:161-167
ISSN: 0741-5214
DOI: 10.1016/j.jvs.2017.12.022
Popis: Retrograde popliteal artery (RPA) access to treat superficial femoral artery and popliteal artery disease is an option when treatment through common femoral artery (CFA) access is not possible. Our goal was to compare the safety and efficacy of RPA access with CFA access for treatment of femoral and popliteal artery lesions.The Vascular Quality Initiative was queried for all patients undergoing RPA access from 2010 to 2016 for symptomatic peripheral arterial disease. These were compared with standard CFA access. Patients with acute limb ischemia were excluded. Preoperative, operative, and postoperative data were analyzed. Perioperative and 6-month outcomes were analyzed. Multivariable analysis was used to assess the effect of RPA access on amputation or death, major adverse limb event (MALE) or death, patency, and death.There were 30,074 patients with isolated superficial femoral and popliteal artery disease treated, 148 of whom had RPA access. Indications overall included claudication (56.3%), rest pain (13.9%), and tissue loss (29.8%). RPA access had a significantly lower rate of technical success compared with CFA access (80.4% vs 93.8%; P .001). RPA access and CFA access were similar for rates of arterial dissection (8.3% vs 6.3%; P = .333), distal embolization (0% vs 1.2%; P = .183), access site hematoma (3.4% vs 3.1%; P = .849), and 30-day mortality (1.4% vs 1.1%; P = .789). There were no differences between RPA access and CFA access for unadjusted 6-month amputation-free survival (94.8% vs 96%; P = .747) or survival (934.3% vs 95.6%; P = .845). MALE-free survival (74.5% vs 83.5%; P = .016) and patency (70.3% vs 83.1%; P .001) were significantly lower in the RPA access group. Multivariable analysis showed no differences between patients who were successfully treated by RPA access and CFA access for amputation-free survival (hazard ratio [HR], 1.24; 95% confidence interval [CI], 0.46-3.32; P = .669), MALE-free survival (HR, 1.57; 95% CI, 0.99-2.5; P = .057), and survival (HR, 0.86; 95% CI, 0.43-1.73; P = .675). RPA access was independently associated with loss of primary patency (HR, 1.91; 95% CI, 1.24-2.94; P = .003).RPA access had lower technical success and primary patency compared with antegrade access at 6 months. There were no differences demonstrated between the two access techniques in perioperative morbidity and mortality or 6-month amputation, MALE, and survival. This technique should be considered when CFA access cannot be accomplished.
Databáze: OpenAIRE